Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Free Cash Flow: 2009-2025

Historic Free Cash Flow for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $18.3 million.

  • Myriad Genetics' Free Cash Flow rose 753.57% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.7 million, marking a year-over-year increase of 82.49%. This contributed to the annual value of -$27.7 million for FY2024, which is 84.09% up from last year.
  • Per Myriad Genetics' latest filing, its Free Cash Flow stood at $18.3 million for Q3 2025, which was up 211.59% from -$16.4 million recorded in Q2 2025.
  • Over the past 5 years, Myriad Genetics' Free Cash Flow peaked at $64.7 million during Q1 2021, and registered a low of -$64.7 million during Q4 2023.
  • Moreover, its 3-year median value for Free Cash Flow was -$19.7 million (2023), whereas its average is -$20.1 million.
  • Per our database at Business Quant, Myriad Genetics' Free Cash Flow slumped by 533.71% in 2022 and then spiked by 753.57% in 2025.
  • Myriad Genetics' Free Cash Flow (Quarterly) stood at -$12.9 million in 2021, then crashed by 69.77% to -$21.9 million in 2022, then slumped by 195.43% to -$64.7 million in 2023, then spiked by 104.64% to $3.0 million in 2024, then soared by 753.57% to $18.3 million in 2025.
  • Its Free Cash Flow stands at $18.3 million for Q3 2025, versus -$16.4 million for Q2 2025 and -$21.6 million for Q1 2025.